Amneal Pharmaceuticals stock heads into October 29 earnings

Published on 10/06/2026 at 13:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amneal Pharmaceuticals stock heads toward its October 29 report after Q2 adjusted EPS reached USD 0.30 versus USD 0.23 consensus. Revenue was USD 796.2 million.

AMRX, US03168L1052, Illustration mit AI erstellt.

Amneal Pharmaceuticals (ISIN US03168L1052) was last at USD 20.35 on Nasdaq on October 5, 2026, with the quarterly report scheduled for October 29. The company enters that date after adjusted second-quarter EPS of USD 0.30 exceeded consensus of USD 0.23, according to Investing.com.

Q2 beat sets the earnings starting point

The adjusted EPS result represented a 30.4 percent beat against the USD 0.23 consensus cited for Q2 2026. Revenue reached USD 796.2 million, above the USD 758.24 million expectation reported by Investing.com.

The standardized Q2 statement shows total revenue of USD 796.197 million, consolidated net income of USD 69.614 million and diluted GAAP EPS of USD 0.18 for the period ended June 30, 2026. The difference between adjusted and GAAP EPS matters because the market comparison uses the adjusted figure, while the reported earnings line uses GAAP accounting.

FDA launch adds a product catalyst

On September 18, 2026, Amneal announced FDA approval and the immediate commercial launch of lanreotide injection in a sterile, single-dose prefilled syringe. The product received Competitive Generic Therapy designation, and the company described it as an addition to its complex injectable portfolio in its September 18, 2026, release.

That launch gives the October report a concrete commercial checkpoint beyond the earnings beat. The main counter-factor is valuation: the October 5 quote implies a trailing P/E of 42.22, while the stock has already gained 95.57 percent over 52 weeks, according to current market statistics published by Stock Analysis.

Consensus target remains above the quote

Stock Analysis lists a Strong Buy consensus from seven analysts and an average price target of USD 22.71. Against the USD 20.35 Nasdaq price, that target lies 11.60 percent above the reference price, while the same page reports a 3-year EPS growth forecast of 20.53 percent.

MarketBeat previously reported eight Buy ratings and one Hold rating, producing a Moderate Buy consensus and a USD 20.14 target in its September 22, 2026, overview. Its report also cited FY 2026 adjusted EPS guidance of USD 0.960-1.060, giving the October print a defined earnings benchmark.

AMRX stock approaches the October report

AMRX was last at USD 20.35 on Nasdaq at 4:00 p.m. ET on October 5, 2026, up USD 0.05, or 0.25 percent, from the prior close. The same session showed a USD 20.23 low and USD 20.59 high, while the 52-week range stood at USD 9.56 to USD 21.18.